{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T16:29:06Z","timestamp":1756571346716,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T00:00:00Z","timestamp":1616457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["D43TW010134"],"award-info":[{"award-number":["D43TW010134"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s00228-021-03116-x","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T08:02:37Z","timestamp":1616486557000},"page":"1341-1348","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of the effects of atazanavir-ritonavir on the pharmacokinetics of lumefantrine in patients living with HIV in Lagos University Teaching Hospital, South-Western Nigeria"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7860-0442","authenticated-orcid":false,"given":"Sikiru Olatunji","family":"Usman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim Adekunle","family":"Oreagba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Rotimi","family":"Kadri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ololade Oluwatosin","family":"Adewumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinwumi","family":"Akinyede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther Oluwatoyin","family":"Agbaje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ganiyu","family":"Abideen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AbdulWasiu Adeniyi","family":"Busari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olayinka Olaiwola","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moshood Olusola","family":"Akinleye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alani Sulaimon","family":"Akanmu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,23]]},"reference":[{"key":"3116_CR1","unstructured":"UNAIDS.Global HIV Statistics 2019. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/UNAIDSFact Sheeten.pdf. Accessed 17 June 2020"},{"issue":"2","key":"3116_CR2","first-page":"103","volume":"26","author":"AS Akanmu","year":"2015","unstructured":"Akanmu AS, Usman SO, Oreagba IA, Agbaje EO, Oshikoya K, Abideen AG, Opanuga OO (2015) Antiretrovirals and co-prescribed drugs for people living with HIV\/AIDS (PLWHA) in a University Teaching Hospital, Southwest Nigeria. West Afr J Pharmacy 26(2):103\u2013115","journal-title":"West Afr J Pharmacy"},{"issue":"1","key":"3116_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.22374\/1710-6222.26.1.1","volume":"26","author":"IA Oreagba","year":"2019","unstructured":"Oreagba IA, Usman SO, Oshikoya KA, Agbaje EO, Akinyede AA, Opanuga OO, Akanmu AS (2019) Clinically significant drug-drug interaction in a large antiretroviral treatment Centre in Lagos, Nigeria. J Popul Ther Clin Pharmacol 26(1):1\u201323","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"3116_CR4","first-page":"123","volume":"9","author":"TE Kwenti","year":"2018","unstructured":"Kwenti TE (2018) Malaria and HIV co-infection in sub-Saharan Africa: prevalence, impact and treatment strategies. Res Rep Trop Med 9:123\u2013136","journal-title":"Res Rep Trop Med"},{"key":"3116_CR5","unstructured":"Federal Republic of Nigeria (2005) National Antimalarial Treatment Policy, FMOH, National malaria and Vector Control Division, Abuja, Nigeria, 2005"},{"key":"3116_CR6","unstructured":"Federal Ministry of Health (2008) National Malaria Control Programme, Abuja, Nigeria. Strategic Plan 2009-2013 Federal Ministry of Health, National Malaria Control Programme"},{"issue":"2","key":"3116_CR7","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2165\/00003088-199937020-00002","volume":"37","author":"NJ White","year":"1999","unstructured":"White NJ, Van Vugt M, Ezzet F (1999) Clinical pharmacokinetics and pharmacodynamics of artemether-lumefantrine. Clin Pharmacokinet 37(2):105\u2013125","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"3116_CR8","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1517\/17425255.3.4.583","volume":"3","author":"A Walubo","year":"2007","unstructured":"Walubo A (2007) The role of cytochrome P450 in antiretroviral drug interactions. Expert Opin Drug Metab Toxicol 3(4):583\u2013598","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3116_CR9","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/1475-2875-8-289","volume":"8","author":"O Bouchaud","year":"2009","unstructured":"Bouchaud O, Imbert P, Touze JT, Dodoo AN, Danis M, Legros F (2009) Fatal cardiotoxicity related to halofantrine: a review based on a worldwide safety data base. Mal J 8:289","journal-title":"Mal J"},{"issue":"9","key":"3116_CR10","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1093\/jac\/dks207","volume":"67","author":"P Byakika-Kibwika","year":"2012","unstructured":"Byakika-Kibwika P, Lamorde M, Mayito J, Nabukeera L, Namakula R, Mayanja-Kizza H (2012) Significant pharmacokinetic interactions between artemether-lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother 67(9):2213\u20132221","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"3116_CR11","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/jac\/dkr596","volume":"67","author":"P Byakika-Kibwika","year":"2012","unstructured":"Byakika-Kibwika P, Lamorde M, Okaba-Kayom V, Mayanja-Kizza H (2012) Lopinavir\/ritonavir significantly influences pharmacokinetic exposure of artemether-lumefantrine in HIV-infected Ugandan adults. J Antimicrob Chemother 67(5):1217\u20131223","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"3116_CR12","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1097\/QAI.0b013e3181acb4ff","volume":"51","author":"P German","year":"2009","unstructured":"German P, Parikh S, Lawrence J (2009) Lopinavir\/ritonavir affects pharmacokinetic exposure of artemether\/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr 51(4):424\u2013429","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3116_CR13","first-page":"30","volume":"16","author":"RM Hoglund","year":"2016","unstructured":"Hoglund RM, Byakika-Kibwika P, Lamorde M, Merry C, Ashton M, Hanpithakpong W (2016) Artemether-lumefantrine co-administration with antiretrovirals: population pharmacokinetics and dosing implications of antiretroviral therapy in HIV-1 infected patients. BMC Infect Dis 16:30\u201336","journal-title":"BMC Infect Dis"},{"issue":"4","key":"3116_CR14","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/bcp.12529","volume":"79","author":"T Kredo","year":"2015","unstructured":"Kredo T, Mauff K, Workman L, Van der Walt JS, Wiesner L, Smith PJ (2015) The interaction between artemether-lumefantrine and lopinavir\/ritonavir-based antiretroviral regimen. Br J Clin Pharmacol 79(4):636\u2013649","journal-title":"Br J Clin Pharmacol"},{"key":"3116_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12936-015-0695-2","volume":"14","author":"BA Maganda","year":"2015","unstructured":"Maganda BA, Ngaimisi E, Kamuhabwa AR, Aklillu E, Minzi OMR (2015) The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment. Mal J 14:179\u2013184","journal-title":"Mal J"},{"issue":"3","key":"3116_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jphs.2020.07.013","volume":"144","author":"SO Usman","year":"2020","unstructured":"Usman SO, Oreagba IA, Akinyede AA, Agbaje EO, Akinleye MO, Onwujuobi AG, Ken-Owotor C, Adeuja O, Ogunfowokan T, Kogbe S, Owolabi ET, Adeniji H, Busari A, Hassan OO, Abideen G, Akanmu AS (2020) Effect of nevirapine, efavirenz and lopinavir-ritonavir on the therapeutic concentration and toxicity of lumefantrine in patients living with HIV in Lagos University Teaching Hospital. J Pharmacol Sci 144(3):95\u2013101","journal-title":"J Pharmacol Sci"},{"key":"3116_CR17","unstructured":"FDA (1997) Guideline on validation of analytical procedures: methodology. (62 FR 27463)"},{"key":"3116_CR18","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/0378-4347(95)00542-0","volume":"681","author":"M Zeng","year":"1996","unstructured":"Zeng M, Lu Z, Yang S, Zhang M, Liao J, Liu S, Teng X (1996) Determination of benflumetol in human plasma by reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr 681:299\u2013306","journal-title":"J Chromatogr"},{"key":"3116_CR19","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1177\/135965350801300702","volume":"13","author":"M Boffito","year":"2008","unstructured":"Boffito M, Else L, Back D, Taylor J, Khoo S, Sousa M (2008) Pharmacokinetics of atazanavir\/ritonavir once daily and lopinavir\/ritonavir twice and once daily over 72 h following drug cessation. Antiviral Therapy 13:901\u2013907","journal-title":"Antiviral Therapy"},{"issue":"3","key":"3116_CR20","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1128\/AAC.44.3.697-704.2000","volume":"44","author":"F Ezzet","year":"2000","unstructured":"Ezzet F, van-Vugt M, Nosten F, Looareesuwan S, White NJ (2000) Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother 44(3):697\u2013704","journal-title":"Antimicrob Agents Chemother"},{"key":"3116_CR21","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1742-7843.2006.pto_249.x","volume":"98","author":"MT Granfors","year":"2006","unstructured":"Granfors MT, Wang JS, Kajosaari L et al (2006) Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol 98:79\u201385","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"3116_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/mi.2007.1","volume":"1","author":"JM Brenchley","year":"2008","unstructured":"Brenchley JM, Douek DC (2008) HIV infection and the gastrointestinal immune system. Mucosal Immunol 1(1):23\u201330","journal-title":"Mucosal Immunol"},{"issue":"8","key":"3116_CR23","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2165\/11592660-000000000-00000","volume":"50","author":"JK Mukonzo","year":"2011","unstructured":"Mukonzo JK, Nanzigu S, Rekic D, Waako P, Roshammar D, Ashton M, Ogwal-Okeng J, Gustafsson LL, Aklillu E (2011) HIV\/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects. Clin Pharmacokinet 50(8):531\u2013540","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"3116_CR24","first-page":"394","volume":"29","author":"L Endrenyi","year":"1991","unstructured":"Endrenyi L, Fritsch S, Yan W (1991) Cmax\/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence. Int J Clin Pharmacol Ther Toxicol 29(10):394\u2013399","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"key":"3116_CR25","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1086\/503423","volume":"42","author":"RN Price","year":"2006","unstructured":"Price RN, Uhlemann AC, van Vugt M, Brockman A, Hutagalung R, Nair S et al (2006) Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Clin Infect Dis 42:1570\u20131577","journal-title":"Clin Infect Dis"},{"key":"3116_CR26","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s12936-016-1327-1","volume":"15","author":"RF Mutagonda","year":"2006","unstructured":"Mutagonda RF, Kamuhabwa AAR, Minzi OMS, Massawe SN, Maganda BA, Aklillu E (2006) Malaria Prevalence, severity and treatment outcome in relation to day 7 lumefantrine plasma concentration in pregnant women. Mal J 15:278","journal-title":"Mal J"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03116-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-021-03116-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03116-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T05:37:39Z","timestamp":1671687459000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-021-03116-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,23]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["3116"],"URL":"https:\/\/doi.org\/10.1007\/s00228-021-03116-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2021,3,23]]},"assertion":[{"value":"7 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Health Research Ethics Committee of the College of Medicine of the University of Lagos (CMUL\/HREC\/06\/18\/354: Sept 2018-Sept 2019).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors gave their consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors gave consent to publish the article in the European Journal of Clinical Pharmacology.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}